Evidence map›Paper›PMID 36225559›Full record

ArticleFrontiers in pharmacology2022

Jia-ga-song-tang protection against alcoholic liver and intestinal damage.

Jiamin Fang, Yuhuan Wu, Changlian Gan, Shufang Ruan, Xiaoliang He, Bixia Wang, Ying Wang, Jingtao Yu, Chuanlan Sang, Dawa Zeren and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Heliyon · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Jiamin FangSchool of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China.
Yuhuan WuSchool of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China.
Changlian GanSchool of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China.
Shufang RuanSchool of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China.
Xiaoliang HeSchool of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China.
Bixia WangSchool of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China.
Ying WangSchool of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China.
Jingtao YuSchool of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China.
Chuanlan SangLaboratory of Experimental Animal, Guangzhou University of Chinese Medicine, Guangzhou, China.
Dawa ZerenResearch Department, University of Tibetan Medicine, Lhasa, China.
Tianqin XiongSchool of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China.
Guangzhou University of Chinese Medicine · CNTibetan Traditional Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gut-liver axis and cellular homeostasis play key roles in alcohol liver disease (ALD). Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) is a stress-sensitive guarantor of cellular homeostasis. We investigated whether the beneficial effects and underlying mechanisms of Jia-ga-song Tang (JGST) against ALD were associated with gut-liver axis and cellular homeostasis. A predictive network depicting the relationship between Jia-Ga-Song-Tang (JGST) and alcoholic liver disease (ALD) was designed by Network pharmacology. Next, 5% v/v Lieber-DeCarli alcohol liquid diet was used to establish the ALD. JGST protected the liver damage, repaired the intestines to alleviate the Two-hit on the liver, and balanced the cellular homeostasis. It was manifested in repairing the liver and intestinal pathological structure, reducing serum ALT, AST, and liver TG, TC, MDA, CAT, and increasing liver GSH, and intestine GSH-Px. JGST mainly inhibited the liver mRNA levels of HO-1, NQO1, GCLC, FASN, and PPARα and activated the intestinal mRNA levels of HO-1 and NQO1, while inhibiting the liver protein levels of HO-1, NQO1. Furthermore, LPS and LBP in the plasma and the expression of inflammatory factors such as IL-1β, TNF-α, IL-6, TGFβ1, CD14, and Myd88 were reduced after treatment to prove that JGST protects the liver from Two-hit. Ethanol was used to intervene in HepG2 and IEC-6 to establish an ALD cell model and treated by Germacrone, ML385, and TBHQ. repaired the intestinal barrier, and inhibited Nrf2 in IEC-6, but protect the HepG2 by activating Nrf2 to balance cellular homeostasis. Our results reinforce that JGST provides an effective protective method for alcoholic liver disease (ALD) by regulating Gut-liver axis and cellular homeostasis.

Indexed as

alcoholic liver diseasejia-ga-song-tangliver protectionnetwork pharmacologyproteomics

Identifiers

PMID36225559
PMCPMC9549243
OpenAlexW4297237536

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.